ArticleTranslational lung cancer research2023

Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced

Dongming Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.